Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

BACKGROUND: Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies. AIMS: Phase 1/2 FUSION NHL 001 was designed to dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Casulo, Carla, Santoro, Armando, Cartron, Guillaume, Ando, Kiyoshi, Munoz, Javier, Le Gouill, Steven, Izutsu, Koji, Rule, Simon, Lugtenburg, Pieternella, Ruan, Jia, Arcaini, Luca, Casadebaig, Marie‐Laure, Fox, Brian, Kilavuz, Nurgul, Rettby, Nils, Dell'Aringa, Justine, Taningco, Lilia, Delarue, Richard, Czuczman, Myron, Witzig, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875673/
https://www.ncbi.nlm.nih.gov/pubmed/35852004
http://dx.doi.org/10.1002/cnr2.1662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875673/
https://www.ncbi.nlm.nih.gov/pubmed/35852004
http://dx.doi.org/10.1002/cnr2.1662

Ejemplares similares